Introduction

Gastric cancer (GC) and adenocarcinomas of the esophagogastric junction (AEG) are aggressive and highly heterogeneous tumors [1]. Due to their critical prognosis following curative resection (R0), adjuvant treatment is the standard of care in most parts of the world. Western world studies advise perioperative chemotherapy or
chemoradiation [2–5], whereas postoperative chemotherapy is the standard of care in East Asia [6–8]. The preferred chemotherapy regimens are based on fluoropyrimidines and platinum compounds which may be combined with epirubicin or docetaxel [1, 8].

GC and AEG have unpredictable responses to cytotoxic treatment and the majority of patients are nonresponders [9, 10]. Nonresponding patients receive toxic treatment with no benefit or even detrimental effects on outcomes [11–14]. The identification of nonresponders before starting perioperative therapy would be of utmost importance. New methods are needed to overcome the limitations of established models in predicting treatment response [15].

Recent studies from our laboratory demonstrated that human cancers can be brought into organotypic slice cultures [16, 17]. This novel method enables to study cytotoxic drug and ionizing radiation effects on individual human cancer probes. A major advantage of this model in contrast to cell culture and cell culture-derived xenograft experiments is the partial preservation of the human tumor microenvironment [16–19]. However, different tumor entities need to be established on its own, as they display distinct growth and culture characteristics, and the complexity of tumor tissue requires careful investigation. For the first time, we could culture tissue slices derived from human GC and AEG and demonstrate their potential for assessment of cytotoxic drug efficacy.

Material and Methods

Preparation and experimental set-up

Fresh surgically sampled human tissue of GC and AEG were obtained after pathological routine diagnostics. Patients were chemonaive or had undergone neoadjuvant chemotherapy. Tumor samples were transported in culture medium and were further processed within 4 to 24 h postextraction. Under sterile conditions, surgical tumor specimens were dissected with an autoclaved razor blade in pieces of a height of 0.5 cm for further preparation. These pieces were cut in 400 μm thick slices using a tissue chopper (McIlwain TC 752; Campden Instruments, Lafayette, IL) and were carefully separated under a stereo microscope with forceps and a scalpel. Then, tissue slices were placed on membrane inserts (Millipore Corporation, Billerica, MA) and were cultured in 6-well plates. Each well contained 1 ml culture medium under the membrane inserts supplying the tissue via diffusion. RPMI-1640 (Gibco, Life technologies, Paisly, UK) culture medium was supplemented with 10% fetal calf serum (Fetal Calf Serum [FCS]; Invitrogen, Darmstadt, Germany), 1% l-glutamine (Gibco), 1% amphotericin B (Carl Roth, Karlsruhe, Germany), and 1% penicillin/streptomycin (Gibco). Slices were incubated in a humidified incubator at 37°C and 5% CO₂ for 2, 4, and 6 days. The culture medium was changed every second day. Slices, which were fixed at the preparation day, were labeled as day 0. Each culture time point was compared with day 0 and is represented by an individual slice.

The study was approved by the ethics committee of the University of Leipzig Medical Faculty. All patients who donated tissue declared their informed consent in written form.

Chemotherapy exposure

Slices were incubated with 5-FU (Medac, Wedel, Germany) and cisplatin (Neocorp, Weilheim, Germany) at different concentrations immediately after cultivation. Drugs were dissolved in 0.9% NaCl and diluted in the culture medium to final concentrations of 3, 10, and 100 μmol/L for 5-FU and 3, 10, and 30 μmol/L for cisplatin. Slices were exposed to cytotoxic treatment over 2–4 days. Drug containing culture medium was freshly prepared before application and changed every other day. Slices of the same tumor that were not exposed to cytotoxic drugs but cultured and fixed simultaneously served as controls.

Staining

Tissue slices were fixed in 4% paraformaldehyde overnight, embedded in paraffin for standard histomorphology using hematoxylin–eosin (H&E) and periodic acid–Schiff (PAS). Cytokeratin stains (CK8 antibody; BioGenex, Fremont, CA: mouse, 1:100 and AE1/3 antibody (CK1–8, 10, 14–16, and 19) are labeled as CK in figures; BioGenex, mouse, 1:50) were used for determining tumor cellularity, Ki-67 (DCS Innovative Diagnostik-Systeme, Hamburg, Germany: rabbit, 1:400) for proliferation, and cleaved caspase-3 staining (Cell Signaling Technology, Danvers, MA: rabbit, 1:400) for apoptosis. CK-positive cells were defined as tumor cells if normal gastric mucosa could not be detected in the H&E stain. A double staining of CK/Ki-67 and CK/cleaved caspase-3 was performed to define the tumor cell viability. After citrate buffer treatment at 95°C for 10 min, sections were washed in 1.5% Triton/PBS, blocked with 5% normal goat serum for 30 min, and incubated overnight at 4°C with primary antibodies. After rinsing sections repeatedly with 1.5% Triton/PBS, primary antibodies were coupled with fluorescent-labeled secondary antibodies (goat-anti-mouse 568, goat-anti-rabbit 488, Alexa Fluor, Invitrogen, Eugene, OR) and nuclei were counterstained with Hoechst 33342 (Sigma, St. Louis, MO).
Analysis of slices

To determine the viability of tissue slices, stained slides were examined under an Olympus BX51 fluorescent microscope (Olympus Deutschland, Hamburg, Germany). Total cell number (Hoechst-positive nuclei) was counted by the ImageJ cell counter plugin (NIH, Bethesda, MD). CK, cleaved caspase-3, and Ki-67-positive cells were counted manually. These three parameters were put in relation to the total cell number and defined as the tumor cell fraction, the apoptosis, and proliferation indices. For determining total cell number and tumor cellularity, six pictures \((n = 6)\) in a 200× magnification per group were taken and counted. Three pictures \((n = 3)\) in a 400× magnification per group were counted for determining apoptosis and proliferation indices. Statistics were accomplished using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA). One-way analysis of variance (ANOVA) was used and \(P < 0.05\) was considered to be statistically significant.

Results

Manufacturing and analysis of slice cultures

Tissue was obtained from 13 patients after resection (nine GCs and four AEGs). Eight cases were used for qualitative and quantitative analysis (see Table S1). In five samples, analysis of slice cultures was not possible due to sparse tumor in the tissue sample (two cases), insufficient interslice comparability (two cases), or fungal infection (one case). A topographical orientation of the surgical tissue sample was needed to trim the samples accurately before slicing. Furthermore, the precise collection of consecutive slices was important to allow for a good interslice comparison within consecutive series. Taking this into account, slice cultures revealed a good preservation of tissue morphology and cellular integrity up to 6 days. GCs of the intestinal and diffuse subtype generally maintained a stable tumor cellularity and stroma preservation (Figs. 1 and 2).

No major difference in cellularity between upper and lower layers could be distinguished in vertical H&E-stained sections (Fig. S1A, B), ruling out a vertical viability gradient caused by diffusion of nutrients from the bottom of the cultures. In line with this observation, induction of apoptosis by 5-FU treatment was also observed along the entire vertical diameter, proving the equal accessibility of cells within the slice for medium components as well as cytotoxic drugs (Fig. S1C and D).

Quantification of stability of slice cultures

Four patients had received neoadjuvant chemotherapy (Fig. 3A) and four patients were chemonaive at the time point of tissue sampling (Fig. 3B). A stable tumor cell fraction until day 6 was observed in five cases. Three cases revealed a distinct decrease in tumor cells between day 2 and day 4 (Fig. 3A and B).

Regarding the total cell count at each culture time point, the majority of cases remained stable until day 6 (data not shown). Neither neoadjuvant chemotherapy nor the
tumor cell fraction measured at day 0 had a major impact on the stability of the tissue slices during cultivation (Fig. 3A and B). Figure 3G–H illustrates tumor cell quantification in one sample (#25).

Figure 4 shows proliferation and apoptosis indices of two different tumor samples using anti-Ki-67 and anti-cleaved caspase-3 immunohistochemistry.

**Cytotoxic treatment in vitro**

After cytotoxic treatment, H&E-stained sections displayed a higher number of fragmented nuclei compared with untreated controls (not shown). Figure 5 illustrates the cytotoxic drug effects in one particular case. A decrease in tumor cellularity (Fig. 5A and B) and an increase in
Figure 3. Quantification of total cell number and tumor cellularity. Panels (A–B) show tumor cellularity of all analyzed cases, while panels (C–H) display observations in one selected case (sample #25). (A) Four patients had received neoadjuvant chemotherapy prior to the sampling of tumor for slice cultivation and (B) four patients had not received any neoadjuvant treatment. In five cases (13, 15, 17, 25, 29), a stable tumor cell fraction until day 6 was observed. Three cases (14, 19, 26) revealed a distinct decrease in tumor cellularity between day 2 and day 4. (C–F) Slice cultures of sample #25 revealed a good preservation of tissue morphology and tumor cell integrity over 2, 4, and 6 days compared with day 0. Stromal cells were dominant in this tumor and the diffuse tumor pattern was difficult to distinguish in H&E stains. Quantification was therefore carried out on the basis of immunohistochemistry (right side). Tumor cells were detected with cytokeratin (CK) antibodies (red) which was combined with nuclear counterstaining (Hoechst 33342, blue). (G) Total cell number remained stable at all culture time points compared with day 0. (H) The tumor cell fraction decreased significantly in this particular case within the first 2 days of cultivation, but remained stable for the further culture period. Fluorescent microscopy, original magnification: 200× in C–F. ±SEM, n = 6.
apoptotic processes (Fig. 5C and D) were observed upon treatment with cisplatin. This effect could be quantified (Fig. 5E and F). However, rather inhomogeneous results of apoptosis indices and higher standard errors were observed in some other cases. Therefore, we decided to use cytokeratin staining reflecting tumor cellularity for further analysis because the results obtained for this parameter were most consistent.

Figure 6 shows one case with a tumor cell fraction above 10% at day 0. The untreated control revealed a dense and compact tumor cellularity. This remained unchanged upon treatment with cisplatin 10 μmol/L, while treatment with 5-FU 10 μmol/L led to a massive decrease in tumor cellularity (Fig. 6A and C).

Three patient samples revealed a low tumor cellularity (4–8% of total cells) at day 0 (stroma predominant tumors). For these cases, we observed that the analysis of chemotherapy effects in vitro is more difficult and leads to greater standard errors (data not shown).

Regarding the other five patient samples (with an initial tumor cellularity above 10%), more reliable values on the >50% reduction in tumor cellularity after cisplatin or 5-FU exposure were observed. Notably, dose-dependent decreases of celluarities were measured, indicating the...
potential of this system for the assessment of individual
drug sensitivities (Fig. S2).

Four samples were exposed to chemotherapy over 4 days
to assess if a prolonged exposure to cytotoxic drugs leads
to more loss of tumor cellularity or increased apoptosis.
But systematic differences between both incubation periods
were not observed (data not shown) indicating that the
shorter incubation time is sufficient for assessing
chemosensitivity.

**Discussion**

To the best of our knowledge, this is the first description
of the successful establishment of ex vivo organotypic
slice cultures of human gastric and esophagogastric junction
cancers. Importantly, we can also show that cytotoxic
drug effects like changes in tumor cellularity, proliferation,
and apoptosis can be assessed in this model making this
new technique an interesting platform for the assessment
of individual drug response.

Inter- and intra-tumoral heterogeneity which are hall-
marks of GC and AEG underscore the need for the
development of more precise and personalized treatment
[20]. The moderate response rates to standard chemo-
therapy and the critical prognosis even after curative
resection demonstrate the need for more efficacious
treatment strategies. This could be reinforced by new
translational research models which provide better treat-
ment responses prediction for perioperative treatment [21].
As a prerequisite, new laboratory-based ex vivo cancer
models should accurately reflect the molecular composi-
tion and heterogeneity of the tumor, including the stroma,
being essential for the evolution of treatment resistance.
In addition, the system should allow for the rapid assess-
ment of cytotoxic drug effects in order to be ready for
use in clinical practice.

Current ex vivo cancer models mainly rely on human
primary cell lines, cell line-derived or patient-derived tumor
xenografts. In contrast to our slice culture model, primary
cell lines are artificial due to the selection of fast-growing
tumor cells during cultivation and the absence of any
stroma. As a consequence, tumor–stroma interactions as
well as heterogeneity are underrepresented [22, 23]. In
tumor xenograft models, a tumor microenvironment
develops, but within murine stroma and in immunocom-
promised animals. This complicates the translation of
findings to the situation in vivo. In addition, establishment
of patient-derived xenografts is time consuming and expen-
sive and may thus not be an ideal tool for use in routine
clinical practice. As previously shown in our laboratory,
slice cultures of human glioblastoma and epithelial head
and neck cancers could be successfully established. We
experienced that each tumor entity needs careful and
distinct investigation regarding the preparation process
and culture conditions [16–18].

In our study, we found that slices of GC and AEG
specimens can be cultured ex vivo over 6 days. We observed
drug-induced tissue alterations and reduction in tumor
cellularity after exposure to varying doses of cisplatin or

**Figure 5.** Effects of cytotoxic drug exposure in GC slice cultures. Slices
from sample #26 were incubated with cisplatin and 5-FU over 2 days
and were then fixed and processed to paraffin sections (7 μm). (A–B)
Tumor cells were visualized using cytokeratin (CK) staining (red); (C–D)
apoptotic cells were visualized using caspase-3 staining (green). Both
were combined with nuclear counterstaining (Hoechst 33342; blue) for
quantitative analysis. (A) Untreated controls showed a dense and
compact tumor cellularity, whereas (B) treated slices revealed a massive
loss of tumor cells. (C) Compared to a minimal number of apoptotic
cells (white arrows) in the untreated control, (D) treatment led to
increased apoptosis. The loss of tumor cells after chemotherapy and the
increase in apoptotic cells are illustrated in the bar graphs (E, F).
Fluorescent microscopy, original magnification: 200× in A–B and 400×
in C–D, ±SEM, n = 6 (CK), n = 3 (caspase-3).
5-FU. Relevant cellular processes, that is, tumor and stromal proliferation as well as apoptosis, were observed. In our view, the advantage of this new system is the preservation of the natural epithelial–stromal architecture and the original tumor tissue morphology. The cultivation period provides sufficient time for investigating response to cytotoxic treatment.

A future challenge will be the establishment of slices derived from endoscopic biopsies which are needed to provide a platform for testing drug response prior to treating a patient in the neoadjuvant setting. Moreover, correlation of ex vivo findings with clinical response and outcome must be examined. Besides, specific molecular characteristics for response or resistance to chemotherapy should be unraveled in the next steps.

In conclusion, slice cultures derived from human gastric and esophagogastric adenocarcinoma have been successfully established and may become an attractive tool for drug response prediction as well as an interesting research model for investigating tumor heterogeneity and molecular features of drug resistance.

Acknowledgments

The authors thank Angela Ehrlich and Constance Hobusch for technical assistance. This study has been supported...
in part by a grant from the German Bundesministerium für Bildung und Forschung (BMBF).

Conflict of Interest

Florian Lordick received research support from GlaxoSmithKline (GSK), Fresenius Biotech, and Merck-Serono (via his institution). He received travel support to scientific meetings from Amgen, Merck-Serono, Roche, and Taiho. He acted as an advisor or speaker (without accepting personal payments) for Amgen, Boston Biomedical, Lilly, Roche, and Taiho. All other authors have no conflicts to disclose.

References

1. Lordick, F., S. Lorenzen, Y. Yamada, and D. Ilson. 2014. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer Off. J. Int. Gastric Cancer Assoc. Jpn. Gastric Cancer Assoc. 17:213–225.

2. Cunningham, D., W. H. Allum, S. P. Stenning, J. N. Thompson, C. J. H. Van de Velde, M. Nicolson, et al. 2006. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355:11–20.

3. Ychou, M., V. Boige, J.-P. Pignon, T. Conroy, O. Bouché, G. Lebréton, et al. 2011. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29:1715–1721.

4. Van Hagen, P., M. C. C. M. Hulshof, J. J. B. van Hulshof, E. W. Steyerberg, M. I. van Berge Henegouwen, B. P. L. Wijnhoven, et al. 2012. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366:2074–2084.

5. Smalley, S. R., J. K. Benedetti, D. G. Haller, S. A. Hundahl, N. C. Estes, J. A. Ajani, et al. 2012. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 30:2327–2333.

6. Sasako, M., S. Sakuramoto, H. Katai, T. Kinoshita, H. Furukawa, T. Yamaguchi, et al. 2011. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29:4387–4393.

7. Bang, Y.-J., Y.-W. Kim, H.-K. Yang, H. C. Chung, Y.-K. Park, K. H. Lee, et al. 2012. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 379:315–321.

8. Moehler, M., C. T. H. Baltin, M. Ebert, W. Fischbach, I. Gockel, L. Grenacher, et al. 2015. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer. 18:550–563.

9. Schmidt, T., L. Sicic, S. Blank, K. Becker, W. Weichert, T. Bruckner, et al. 2014. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br. J. Cancer 110:1712–1720.

10. Blank, S., F. Lordick, F. Bader, M. Burian, M. Dobritz, L. Grenacher, et al. 2015. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation. Gastric Cancer 18:314–325.

11. Lowy, A. M., P. F. Mansfield, S. D. Leach, R. Pazdur, P. Dumas, and J. A. Ajani. 1999. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann. Surg. 229:303–308.

12. Mansour, J. C., L. Tang, M. Shah, D. Bentrem, D. S. Klimstra, M. Gonen, et al. 2007. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann. Surg. Oncol. 14:3412–3418.

13. Kelsen, D. P., K. A. Winter, L. L. Gunderson, J. Mortimer, N. C. Estes, D. G. Haller, et al. 2007. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 25:3719–3725.

14. Lordick, F., K. Ott, B.-J. Krause, W. A. Weber, K. Becker, H. J. Stein, et al. 2007. PET to assess early metabolic response and to guide treatment of adeno- carcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8:797–805.

15. Sasako, M., M. Terashima, W. Ichikawa, A. Ochiai, K. Kitada, I. Kurahashi, et al. 2015. Impact of the expression of thymidylate synthase and dihydropteroate dehydrogenase genes on survival in stage II/III gastric cancer. Gastric Cancer. 18:538–548.

16. Meixensberger, A. Gutenberg, et al. 2013. Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments. Neuro-Oncol. 15:670–681.

17. Gerlach, M. M., F. Merz, G. Wichmann, C. Kubick, C. Wittekind, F. Lordick, et al. 2013. Slice cultures from head and neck squamous cell carcinoma: a novel test.
system for drug susceptibility and mechanisms of resistance. Br. J. Cancer 110:479–488.
18. Vaira, V., G. Fedele, S. Pyne, E. Fasoli, G. Zadra, D. Bailey, et al. 2010. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc. Natl. Acad. Sci. USA 107:8352–8356.
19. Holliday, D. L., M. A. Moss, S. Pollock, S. Lane, A. M. Shaaban, R. Millican-Slater, et al. 2013. The practicalities of using tissue slices as preclinical organotypic breast cancer models. J. Clin. Pathol. 66:253–255.
20. Lordick, F., W. Allum, F. Carneiro, E. Mitry, J. Tabernerlo, P. Tan, et al. 2014. Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat. Rev. 40:692–700.
21. Miao, R.-L. 2014. Towards personalized perioperative treatment for advanced gastric cancer. World J. Gastroenterol. 20:11586.
22. Hughes, P., D. Marshall, Y. Reid, H. Parkes, and C. Gelber. The costs of using unauthenticated, over-passaged cell lines: how much more data do we need? 2007. Biotechniques. 43:575, 577–578, 581–582 passim.
23. Kamb, A. 2005. What’s wrong with our cancer models? Nat. Rev. Drug Discov. 4:161–165.

Supporting Information

Additional supporting information may be found in the online version of this article:

Figure S1. Characteristics of slice cultures.
Figure S2. Tumor cellularity after cytotoxic drug exposure (all cases).
Table S1. Patient and treatment characteristics of all samples used for slice culture experiments.